BTIG Research Reiterates “Buy” Rating for ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reiterated by BTIG Research in a note issued to investors on Thursday,Benzinga reports. They currently have a $12.00 price target on the stock. BTIG Research’s price objective would indicate a potential upside of 49.07% from the stock’s current price.

Several other brokerages have also weighed in on IBRX. The Goldman Sachs Group reiterated a “buy” rating on shares of ImmunityBio in a report on Monday, February 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a research report on Tuesday, April 14th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of ImmunityBio in a research report on Wednesday. D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 price objective on shares of ImmunityBio in a research report on Tuesday, May 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $12.00 price objective (up from $7.00) on shares of ImmunityBio in a research report on Wednesday, March 4th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, ImmunityBio has a consensus rating of “Moderate Buy” and a consensus target price of $14.20.

ImmunityBio Stock Up 3.7%

ImmunityBio stock opened at $8.05 on Thursday. ImmunityBio has a 52 week low of $1.95 and a 52 week high of $12.43. The firm’s 50-day simple moving average is $7.77 and its 200 day simple moving average is $5.53. The firm has a market capitalization of $8.43 billion, a PE ratio of -9.47 and a beta of 0.02.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.54). The business had revenue of $44.21 million for the quarter, compared to the consensus estimate of $43.07 million. On average, research analysts expect that ImmunityBio will post -0.31 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Barry J. Simon sold 75,000 shares of ImmunityBio stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total transaction of $900,750.00. Following the sale, the director directly owned 2,850,821 shares in the company, valued at $34,238,360.21. The trade was a 2.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 275,000 shares of company stock worth $2,934,500 over the last quarter. 69.48% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ImmunityBio

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in ImmunityBio by 18.5% in the 4th quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock worth $64,899,000 after purchasing an additional 5,122,052 shares in the last quarter. State Street Corp lifted its holdings in shares of ImmunityBio by 45.4% during the 4th quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after buying an additional 5,139,890 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of ImmunityBio by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock valued at $15,684,000 after buying an additional 1,030,113 shares during the last quarter. Heights Capital Management Inc. acquired a new stake in shares of ImmunityBio during the 3rd quarter valued at about $16,152,000. Finally, Goldman Sachs Group Inc. lifted its holdings in ImmunityBio by 439.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock worth $12,182,000 after purchasing an additional 5,012,001 shares during the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.

Key Stories Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: The FDA accepted ImmunityBio’s supplemental BLA for ANKTIVA plus BCG, creating a clear regulatory path toward a potential label expansion and a January 6, 2027 decision date. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy rating on IBRX, with a $15 price target, reinforcing bullish sentiment after the FDA review news. Article Title
• Positive Sentiment: ImmunityBio also highlighted favorable comparative-effectiveness data for ANKTIVA + BCG versus competing bladder cancer therapies, which may support the product’s commercial outlook. Article Title
• Neutral Sentiment: Several firms issued class-action reminders tied to the FDA warning letter over allegedly misleading cancer treatment claims, keeping legal overhang in focus for investors. Article Title
• Neutral Sentiment: Analyst commentary on ImmunityBio’s valuation after the FDA approval for Anktiva suggests the stock may be consolidating after the initial move. Article Title

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.